Antipsychotics can induce in schizophrenic (SZ) and bipolar disorder (BP) patients serious body weight changes that increase risk for noncompliance to medication, and risk for cardiovascular diseases and diabetes. A genetic origin for this susceptibility to weight changes has been hypothesized because only a proportion of treated patients are affected, the degree of affection differing also in rates and magnitudes. In a first genome scan on obesity under antipsychotics in SZ and BP, we analyzed 21 multigenerational kindreds (508 family members) including several patients treated for a minimum of 3 years mainly with haloperidol or chlopromazine. Obesity was defined from medical files and was shown to be 2.5 times more frequent in patients treated with antipsychotics than in untreated family members (30 vs 12%). The nine pedigrees that showed at least two occurrences of obesity under antipsychotics were submitted to model-based linkage analyses. We observed a suggestive linkage with a multipoint Lod score (MLS) of 2.74 at 12q24. This linkage finding vanished when we used as phenotypes, obesity unrelated to antipsychotics, and when we used SZ or BP. This suggests that this positive linkage result with obesity is specific to the use of antipsychotics. A potential candidate gene for this linkage is the pro-melanin-concentrating hormone (PMCH) gene located at less then 1 cM of the linkage. PMCH encodes a neuropeptide involved in the control of food intake, energy expenditure, and in anxiety/depression. This first genome scan targeting the obesity side effect of antipsychotics identified 12q24 as a susceptibility region. Keywords: schizophrenia; bipolar disorder; melanin-concentrating hormone Adverse metabolic effects of antipsychotics such as weight gain may contribute to noncompliance with treatment and may lead to medical morbidity when obesity is reached.
Adverse metabolic effects of antipsychotics such as weight gain may contribute to noncompliance with treatment and may lead to medical morbidity when obesity is reached. 1 Indeed, obesity, as defined by a body mass index (BMI) of 30 kg/m 2 and greater 2 is associated with higher risks of developing cardiovascular diseases, hypertension, type II diabetes, dyslipidemia, arthritis, and some forms of cancer. The estimate of the proportion of schizophrenic (SZ)-or bipolar disorder (BP)-treated patients experiencing significant weight gain for a given antipsychotic varies between 10 and 50%, according to the population studied, and the dose and the duration of the follow-up. For example, 25% of the patients treated with fluphenazine experienced significant weight gain after 1 month, and this proportion reaches 50% in 1 year. 3 In patients treated with olanzapine for up to 3 years, weight gain tended toward a plateau at approximately 36 weeks. 4 The proportion of patients experiencing weight gain also varies according to the antipsychotic used, the greatest proportion being observed with olanzapine and clozapine, followed by chlorpromazine and thioridazine/ mesoridazine, and the lowest with ziprasidone and molindone, the latter even inducing a weight loss. 5 Antipsychotics can also induce other metabolic perturbations such as hyperglycemia, insulin resistance and diabetes, and dyslipidemia. For instance, we showed that despite a similar body weight, olanzapine-treated SZ patients showed higher levels of plasma triglycerides and very low-density lipoprotein cholesterol than risperidone-treated SZ. 6 Moreover, we also observed that 32% of the olanzapine patients in contrast to 5% of those on risperidone were characterized by the atherogenic metabolic triad. 6 Hence, beyond the differences related to the drug used and the duration of follow-up, important interindividual differences exist in terms of the liability for weight gain and metabolic perturbations under antipsychotic treatment. Indeed, even under the highly standardized treatment conditions of drug trials, only a proportion of subjects showed these side effects. Because of these interindividual differences, as well as the relatively high heritability of obesity, 7 the susceptibility to body weight change in psychotic patients as a side effect of antipsychotics has been hypothesized to be of genetic origin.
Variations in genes related to the neurotransmitter systems affected by antipsychotics are prime candidates to explain the interindividual differences in weight gain in psychotic patients, following exposure to antipsychotics. These neurotransmitter systems include the serotonergic, dopaminergic, alpha adrenergic, muscarinic, histaminergic, and cholinergic neurotransmitter systems 8, 9 for which antipsychotics show various profiles of affinity. 10 The serotonergic system has been the main target of candidate gene studies of antipsychotic-induced weight gain and metabolic perturbations. Serotonin receptor 5-HT 2C is located in human chromosome Xq24, and it was reported in knockout mice for 5-HT 2C, a leptinindependent hyperphagia resulting in obesity and type II diabetes. 11 Associations have also been reported in humans between 5-HT 2C and BMI, 12 between 5-HT 2A and energy intake in obese subjects, 13 and between 5-HT 1B and minimum lifetime BMI in women with bulimia nervosa, 14 whereas no association was observed with the 5-HT 2C Cys23Ser polymorphism and body weight gain. 15 Reynolds et al 16 analyzed the 5-HT 2C À759C/T polymorphism in firstepisode patients treated with chlorpromazine or risperidone, and those carrying the À759T variant showed an antipsychotic-induced weight gain 3 times lower.
The possible role of genes involved in the metabolism of antipsychotics has also been studied. For instance, cytochrome P450 CYP2D6 enzyme metabolizes many drugs including antipsychotics, with its activity ranging from complete deficiency to ultrafast metabolism depending on at least 16 different known alleles. 17 A significant genotype effect of a CYP2D6 polymorphism on percent change of BMI in 11 patients under olanzapine has been reported. 18 Basile et al 19 have tested nine candidate genes, including the cytochrome P450 1A2 in 80 DSM-IV SZ patients prospectively assessed for clozapineinduced weight gain. No significant difference in weight gain was observed between genotypes of the different polymorphisms using covariance analysis, but some trends were observed for 5-HT 2C , the b3 and a1a-adrenergic receptors, and the tumor necrosis factor alpha (TNFa). 19 Finally, Reynolds 20 reported a lower weight gain under chlorpromazine or risperidone in SZ patients carrying the G allele of the 2548A/G polymorphism in the promoter of the leptin gene indicating that a gene involved in appetite and fat mass regulation could also be associated with the side effect of antipsychotics on body weight.
These prior studies on the genetics of antipsychotic-induced weight gain and metabolic perturbations relied on a candidate gene approach. Given limited a priori knowledge on the pathophysiology of these side effects, linkage studies offer a significant advantage, since they do not depend on such a priori information. To our knowledge, no such linkage study of obesity in antipsychotic-treated psychotic patients has yet been reported.
To investigate this possible genomic hypothesis of the occurrence of obesity in patients treated with antipsychotics, we took advantage of 21 already collected multigenerational families presenting multiple incidences of SZ and BP and on which we reported a genome scan. 21 We use these genotypes to redo the linkage analysis on a phenotype of obesity under antipsychotics (ObA) among nine of these pedigrees showing at least two ObA occurrences. We hypothesized that the obesity side effect observed in a subgroup of antipsychotic-treated patients is expressed only when an appropriate combination of different genetic variants is present. Different genetic variant combinations would be responsible for the variations in magnitude, rate, and kinetics of obesity in a given environment. A suggestive linkage on chromosome 12 has been detected.
Material and methods

Subjects
A total of 21 multigenerational kindred affected by SZ or BP, including 508 family members, were ascertained and diagnosed using a lifetime best estimate consensus (DSM-III-R) procedure. The ascertainment and Ethics Committee approval have already been reported. 21, 22 All patients received various antipsychotics for at least 3 years. The history of antipsychotic medication was drawn from the lifetime medical records of the subjects. 23 The mean age of onset was 25.4 (78.5) years for SZ and 28.8 (710.3) years for BP, and the mean current age was 43.8 and 56.4 years, respectively. The medical and nursing notes from all medical records, in-and out-patients across life, were reviewed. A phenotype of ObA was diagnosed, blind to genotypes, when clear written notes about obesity from psychiatrists or nurses were recorded (N ¼ 39). Patients for whom a light excess of weight or a healthy weight was clearly noted were rated as non-ObA (N ¼ 89). Those having no indication of corpulence status were classified as unknown and were not used in the linkage analyses. In order to assess the specificity of the linkage results to antipsychotic effect on obesity, linkage analyses were also performed using an obesity (Ob) phenotype that included all ObA cases and Ob present in family members, who were not taking antipsychotics. Linkage results with ObA were also contrasted with those obtained with the SZ and BP phenotypes themselves (see Mazaide et al 24 for definitions) allowing to distinguish ObA linkages from linkages related to liability to SZ or BP.
Genotyping
Our genome scan on the SZ/BP cohort 21, 22 included 470 microsatellite markers with a mean spacing of 6.5 centimorgan (cM), according to the Genetic Location DataBase (LDB) maps (http://cedar.genetics.soton.ac.uk/). For genotyping, we used radioactive tagging of PCR products and visual genotyping, 21, 22 , or an automated genotyping procedure (SAGA; LiCor) based on laser infrared automatic DNA sequencers (LiCor) 25 , where genotypes were confirmed visually. Mendelian inheritance of genotypes was checked including all family members (PedCheck software 26 ), and accuracy of the genotyping was evaluated by adding blind duplicates to the DNA samples.
Linkage analysis
Only pedigrees with at least two occurrences of ObA could be included in the analysis. Model-based linkage analyses were used since growing evidence shows that they are more powerful than model-free or nonparametric analyses 27, 28 even when the mode of inheritance specified is only approximately correct, provided that at least one dominant and one recessive model are considered. 29 We considered both a complete and a reduced penetrance model for each dominant and recessive transmission ( Table 1) . The analyses were first carried out using both affected and unaffected (AU) patients, and then using affectedonly (AO) to reduce the impact of a mis-specification in the penetrance parameter. When analyzing the ObA phenotype, (i) ObA patients were classified as affected, (ii) the non-ObA as unaffected, and (iii) the Ob or non-Ob family-related subjects without antipsychotic as unknown ( Table 2) . The linkage signals were classified as being either suggestive (Lod scores between 2.5 and 3.9) according to Lander and Kruglyak thresholds 30 adjusted for multiple testing, 31 or promising (Lod scores greater than 1.2) according to Rao and Province. 32 No significant Lod score (43.9) 30,31 was observed with ObA in this study in contrast with those previously reported in this sample with SZ and BP phenotypes. 22 Results Table 2 shows the antipsychotics used by the patients included in the linkage study. Among the 13 different antipsychotics prescribed, the two most frequently used were haloperidol taken alone (23%) or combined with another antipsychotic (7%), and chlorpromazine (13 and 8%, respectively). The rate of methotrimeprazine was 12% (4% alone, 8% combined with other antipsychotics), fluphenazine 9%, and thioridazine 8%. Finally, perphenazine and risperidone, the latter being the only atypical antipsychotic, each have a 7% rate. Other antipsychotics were prescribed at a frequency of less than 2%. Five patients received different combinations of three drugs at the same time (see footnote of Table 2 ). Some 44% of the patients who previously received a different antipsychotic were currently on haloperidol, 22% were on chlorpromazine, and 10% on fluphenazine. On the other hand, some 21% of patients had also received lithium, and 6% various antidepressants. One patient received benzodiazepine. Table 3 shows the distribution of the subjects according to their obesity status. Among the 128 patients treated with antipsychotics, 30% (39/128) developed obesity compared to 12% (18/150) in untreated relatives. Table 3 suggests that obesity tended to show familial aggregation in our sample. For example, seven out of nine patients under antipsychotics became obese in family 230, whereas six patients out of eight treated with antipsychotics remained at an acceptable weight in pedigree 105A (Table 3) . Nine out of our 21 pedigrees ( (Table 4 ). However, some of the linkage signals with ObA in these regions were also detected (Lod41.2) with Ob, for example, at 1p36 and 6p21, or with SZ or BP at 6p21 and 15q26, with most linkages going down in multipoint analysis (Table 4) .
Discussion
The chromosomal region 12q24 showed the strongest linkage results with obesity in patients taking antipsychotics (Table 4 ; Figure 1 ), which suggests that a locus for ObA is located within this region. Moreover, no linkage signal was observed with the obesity alone phenotype or with SZ or BP, which suggests a specificity of this linkage to the ObA phenotype.
The current results must be interpreted taking into account the following methodological issues and limitations. First, we assessed the power of The penetrance values refer to the probability of having a given affection status conditional to the age class and to each of the three possible genotypes at the disease locus, that is, dd, Dd, and DD where the allele D identifies the susceptibility allele (for unaffected subjects, the linkage program will use one of these values). The diagonal reports the percentage of those receiving only one antipsychotic, and below the diagonal, the percentages of those receiving two antipsychotics. Above the diagonal, the percentages of those having previously taken other antipsychotics are indicated. For example, 43.7% of patients using haloperidol have also taken previously other antipsychotics. The number of patients having taken three drugs are the following: chlorpromazine-thioproperazine-methotrimeprazine: 1; chlorpromazine-thioproperazineperphenazine: 1; haloperidol-chlorpromazine-thioproperazine: 1; haloperidol-chlorpromazine-methotrimeprazine: 1; thioridazine-pimozide-perphenazine: 1; haloperidol-chlorpromazine-lithium: 2; haloperidol-trifluoperazine-lithium: 1.
parametric analyses in the nine families under study by simulations with SLINK and MSIM. 33 The ELOD was 3.8 and the power to observe a Lod score over 2.5 (suggestive linkage) and 3.9 (significant linkage) was 74 and 44%, respectively. In these simulations, we observed one suggestive Lod score of 2.74 and no significant linkage. Given the expected power of this subsample, even if this result did not reach our stringent threshold for significance, this result can be considered as a fairly clear evidence of linkage.
Second, we obtained weaker linkage evidence using the affected-only phenotype (data not shown) than using affected/nonaffected analyses. This suggests that few antipsychotic-treated patients were nonpenetrant for the ObA phenotype, that is, there were few carriers of the gene variations who did not develop the ObA phenotype while taking antipsychotics. This may be related to the fact that the psychotic patients included had to receive antipsychotics for at least 3 years, which provided enough time for ObA to develop completely. Third, it is also possible that some patients were obese before beginning antipsychotics. Then, it can be argued that our linkage signal at 12q24 could be related to general obesity rather than to treatmentrelated obesity. However, our linkage analysis, including all obese patients and related family members, did not yield linkage evidence in this chromosomal region, which supports the specificity of this linkage signal to treatement-related obesity.
Fourth, our phenotype definition of obesity, although made blind and based on the extensive The models refer to those described in Table 1 . Note that all these results were obtained using an affected-unaffected definition. b Z max is the two-point lod score. c MLS is the multipoint lod score. d Suggestive result (2.5rLodr3.9) [30, 31] is indicated in bold in contrast to promising results (LodZ1.2) [32] .
contemporary lifetime information from all medical records, is nevertheless less optimal than direct concurrent measures. In fact, the analyzed cohort was not initially designed to study a phenotype of obesity, and this phenotype was developed from the written notes from psychiatrists and nurses in the medical records of the psychotic patients. This is a potential limitation of the study. To estimate the reliability on misclassification rate for ObA, we gathered a direct measurement of BMI in 21 patients included in the current study. We observed a misclassification rate of around 10% since two patients were misclassified as non-ObA while showing a BMI greater than 30 kg/m 2 . However, such potential errors in measure would have generated type 2 (false negative) rather than type 1 (false positive) errors in linkage. Indeed, previous work by Martinez et al 34 has shown that phenotypic misclassification leads to 'yan overestimation of the recombination fraction and a loss of power of the linkage test'. This statement applies both to false positive (ie, non-ObA subjects erroneously classified ObA) and false negative (ie, ObA subjects erroneously classified non-ObA) phenotypic assignments.
Fifth, the genes involved in the genetic control of the side effects of antipsychotics may vary according to the drug used. Our patients were treated with a variety of antipsychotics (mainly haloperidol or chlorpromazine), which is unavoidable in linkage studies in which the standardization of drug treatment is very difficult. Additionally, a significant number of patients had previously received antipsychotics other than those currently used (Table 2) . Thus, the linkage signal that we observed may be related to a common liability to weight gain under chlorpromazine or haloperidol. However, additionnal loci may also be involved in mediating side effects of other antipsychotics.
According to the LDB genetic map, the linked region on chromosome 12q24 (Figure 1 ) is located at less than 1 cM from the pro-melanin-concentrating hormone (PMCH) gene, encoding in rodents a known orexigenic neuropeptide. On the other hand, according to the physical map from the Human Genome Sequence project (NCBI) the linked region becomes closer (0.05 megabases) to a cluster of genes including the cerebrellar ataxia 2 (SCA2) and the non-insulindependant diabetes mellitus II (NIDDM2) loci than to the PMCH locus (16 megabases). Also, two expressed transcript sequences (HS.240246 and HS.131598) with no known protein similarity are located very close to our linkage with ObA ( Figure 1 ). However, Figure 1 Linkage results at 12q24 with surrounding genes, ESTs and markers according to genetic (G) or physical (P) maps. PMCH: pro-melanin-concentrating hormone; SCA2: spinocerebrellar ataxia 2; NIDDM2: non-insulin-dependent mellitus 2; M: megabase; MLS: multipoint Lod score. our strongest linked marker D12S79 showed two locations on the physical map, which casts doubts on its real physical location. PMCH should be retained as a strong candidate for ObA in this region because of its very close location to our linked marker according to the LDB genetic map. Since the LDB map has been used for locating the markers in linkage analysis, this map should be more representative of the location of the linked markers. Moreover, numerous observations support PMCH as the candidate gene for antipsychotic-induced obesity. For instance, PMCH is overexpressed in the hypothalamus of ob/ob mice lacking the leptin gene; 35 fasting, increasing its expression. When injected in the lateral ventricles of rats, food consumption increased indicating an orexigenic effect. 35 Mice deficient in MCH (PMCH knockout mice) have reduced body weight and leanness due to both hypophagia and an inappropriately increased metabolic rate. Inversely, transgenic mice overexpressing MCH become obese and insulin resistant. 36 Additionally, PMCH knockout mice showed a reduced amount of leptin and pro-opiomelanocortin mRNA, 37 which indicates that MCH works downstream to the leptin and melanocortin systems. Two MCH receptors (MCHR1, MCHR2) are known in humans, and MCHR1-deficient mice have normal body weight but, surprisingly, are hyperphagic, their leanness being a consequence of hyperactivity and of an altered metabolism. 38 Moreover, it has been reported that the synaptosomal associated protein SNAP-7941, a specific antagonist of MCHR1, not only inhibited food intake stimulated by a central administration of MCH in rats, but also produced effects similar to clinically used antidepressants and anxiolytics in three animal models of depression/anxiety. 39 Hence, the MCH pathway is involved in both body weight and mood status regulations, and it remains to be shown how antipsychotics may influence these regulations.
Other linkages, even being weak and showing some divergences according to the 2-point and MLS results, or showing some linkages with either Ob, SZ, or BP, are close to other possible candidate genes for obesity antipsychotic side effects. These included two known antipsychotic targets at 1p36 (serotonin receptor 6; HTR6) and 15q26 (cholinergic receptor muscarinic 5; CHRM5), and at 6p21, the TNFa system. HTR6 is known to have an affinity for antipsychotics, particularly haloperidol, which is the principal antipsychotic used in our study. 5-HT2c, another member of this family of receptors, is associated with antipsychotic effects on body weight. 40 The clinical implications of CHRM5 is actually unknown. However, the muscarinic receptors are known to bind antipsychotics, 41 and mice lacking the muscarinic receptor 3 are hypophagic and lean, 42 whereas the blockade of the cortical muscarinic receptor inhibited the memory of taste. 43 Finally, TNFa is activated by psychotropic drugs that lead to weight gain, 44 and is known to play a role in reducing adipose tissue mass. 45 An earlier study did not find a significant association between a -308G/A single nucleotide polymorphism located in the promoter region of TNFa and weight changes following 6 weeks of clozapine medication. 19 However, this study could suffer from a lack of power since only three out of 74 patients were found as homozygote A/A, where twice the amount of body weight change was shown in contrast to A/G and G/G genotypes (P ¼ 0.15). Also, patients were treated for a relatively short period of time (6 weeks) in contrast, for example, to our study, where patients received antipsychotics for at least 3 years, thus allowing complete penetrance of the obesity phenotype.
In conclusion, our results supported the hypothesis that the obesity observed in the SZ or BP patients treated with antipsychotics could be genetic in origin, and that the chromosomal region 12q24 includes a gene that may be involved. They also raise the hypothesis that variations in genes directly involved in body composition, such as, possibly PMCH, in contrast with those being known targets of antipsychotics, such as the serotonin receptors, could also be involved in the side effects of antipsychotics on body weight in psychotic patients.
